Page last updated: 2024-08-24

3-iodobenzylguanidine and Sclerosis, Systemic

3-iodobenzylguanidine has been researched along with Sclerosis, Systemic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujimoto, M; Hasegawa, M; Kawano, M; Nakajima, K; Takehara, K; Taki, J; Tonami, N1
Gürtner, C; Holzmann, H; Hör, G; Krause, BJ; Wendt, T; Werner, RJ; Winten, G1

Other Studies

2 other study(ies) available for 3-iodobenzylguanidine and Sclerosis, Systemic

ArticleYear
Myocardial damages in systemic sclerosis detected by gated myocardial perfusion SPECT and sympathetic imaging.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:11

    Topics: 3-Iodobenzylguanidine; Adult; Aged; Diastole; Female; Heart; Heart Diseases; Humans; Male; Middle Aged; Myocardium; Radiopharmaceuticals; Scleroderma, Systemic; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left

2006
Early diagnosis of cardiac involvement in systemic sclerosis by 123I-MIBG neurotransmitter scintigraphy.
    Nuclear medicine communications, 1998, Volume: 19, Issue:9

    Topics: 3-Iodobenzylguanidine; Adult; Aged; Arrhythmias, Cardiac; Biological Transport; Female; Heart; Humans; Male; Middle Aged; Myocardium; Prognosis; Radiopharmaceuticals; Raynaud Disease; Scleroderma, Systemic; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

1998